CL2015001237A1 - Anticuerpos anti-receptor de procineticinas (prokr) y usos de los mismos. - Google Patents
Anticuerpos anti-receptor de procineticinas (prokr) y usos de los mismos.Info
- Publication number
- CL2015001237A1 CL2015001237A1 CL2015001237A CL2015001237A CL2015001237A1 CL 2015001237 A1 CL2015001237 A1 CL 2015001237A1 CL 2015001237 A CL2015001237 A CL 2015001237A CL 2015001237 A CL2015001237 A CL 2015001237A CL 2015001237 A1 CL2015001237 A1 CL 2015001237A1
- Authority
- CL
- Chile
- Prior art keywords
- procineticin
- prokr
- antibodies
- receptor
- procineticin receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261725704P | 2012-11-13 | 2012-11-13 | |
| US201361825112P | 2013-05-20 | 2013-05-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2015001237A1 true CL2015001237A1 (es) | 2015-08-28 |
Family
ID=49667597
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2015001237A CL2015001237A1 (es) | 2012-11-13 | 2015-05-08 | Anticuerpos anti-receptor de procineticinas (prokr) y usos de los mismos. |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US20140134189A1 (es) |
| EP (1) | EP2920211A1 (es) |
| JP (1) | JP2016502520A (es) |
| KR (1) | KR20150084007A (es) |
| CN (1) | CN104781280A (es) |
| AU (1) | AU2013345018A1 (es) |
| BR (1) | BR112015010691A2 (es) |
| CA (1) | CA2891327A1 (es) |
| CL (1) | CL2015001237A1 (es) |
| CO (1) | CO7400866A2 (es) |
| EA (1) | EA201590877A1 (es) |
| HK (1) | HK1210182A1 (es) |
| IL (1) | IL238629A0 (es) |
| MX (1) | MX2015005546A (es) |
| PH (1) | PH12015500903A1 (es) |
| SG (1) | SG11201502933UA (es) |
| WO (1) | WO2014078306A1 (es) |
| ZA (1) | ZA201502516B (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI774028B (zh) | 2015-01-30 | 2022-08-11 | 學校法人埼玉醫科大學 | 抗ａｌｋ２抗體及其用途 |
| KR20210133261A (ko) * | 2019-02-26 | 2021-11-05 | 소렌토 쎄라퓨틱스, 인코포레이티드 | Bcma에 결합하는 항원 결합 단백질 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5891720A (en) | 1997-04-17 | 1999-04-06 | Millennium Pharmaceuticals, Inc. | Isolated DNA encoding a novel human G-protein coupled receptor |
| EP1147136A4 (en) | 1998-12-10 | 2003-04-16 | Synaptic Pharma Corp | DNA CODED FOR A MAMMAL RECEPTOR (fb41a) AND THEIR USE |
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| NZ518662A (en) | 1999-11-17 | 2004-10-29 | Arena Pharm Inc | Endogenous and non-endogenous versions of human G protein-coupled receptors |
| AU2001272735A1 (en) | 2000-07-18 | 2002-01-30 | Takeda Chemical Industries Ltd. | Novel physiologically active peptide and use thereof |
| US6902902B2 (en) | 2001-11-27 | 2005-06-07 | Arena Pharmaceuticals, Inc. | Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders |
| DE10229379A1 (de) | 2002-06-26 | 2004-01-29 | Schering Ag | EG-VEGF Rezeptor Antagonisten |
| AU2003286697A1 (en) | 2002-10-25 | 2004-05-13 | Norak Biosciences, Inc. | Methods of identifying reduced internalization transmembrane receptor agonists |
| WO2004087054A2 (en) | 2003-03-25 | 2004-10-14 | The Regents Of The University Of California | Methods for modulating gastric secretion using prokineticin receptor antagonists. |
| GB0320238D0 (en) | 2003-08-29 | 2003-10-01 | Medical Res Council | Treatment of disease |
| CN101326168A (zh) | 2005-03-24 | 2008-12-17 | 詹森药业有限公司 | 激肽原1受体拮抗剂 |
| CN102585002A (zh) | 2006-06-02 | 2012-07-18 | 瑞泽恩制药公司 | 人il-6受体的高亲和力抗体 |
| NO347649B1 (no) | 2006-12-14 | 2024-02-12 | Regeneron Pharma | Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse. |
| ITRM20070182A1 (it) * | 2007-04-03 | 2008-10-04 | Univ Roma | Antagonisti dei recettori delle prochineticine derivati di essi e loro uso |
| JP5425056B2 (ja) | 2007-05-15 | 2014-02-26 | エフ．ホフマン−ラ ロシュ アーゲー | Ｇタンパク質共役受容体（ｇｐｃｒ）に対する抗体 |
| US20100286021A1 (en) | 2007-09-25 | 2010-11-11 | Qun-Yong Zhou | Methods of Modulating Prokineticin 2 for Treatment of Stress Response and Anxiety-Related Disorders |
| US8722896B2 (en) * | 2008-12-17 | 2014-05-13 | The Regents Of The University Of California | Prokineticin receptor antagonists and uses thereof |
| JO3182B1 (ar) | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
| JO3375B1 (ar) * | 2010-11-08 | 2019-03-13 | Regeneron Pharma | أجسام مضادة بشرية للجين a1 الشبيه بعامل النخر الورمي (tl1a) |
| ITMI20111225A1 (it) * | 2011-06-30 | 2012-12-31 | Fond I R C C S Istituto Neur Ologico Carlo | Uso di antagonisti non peptidici dei recettori per le prokineticine per la terapia di malattie autoimmuni o con componente autoimmune, o di malattie disimmuni o con componente disimmune |
-
2013
- 2013-11-12 MX MX2015005546A patent/MX2015005546A/es unknown
- 2013-11-12 SG SG11201502933UA patent/SG11201502933UA/en unknown
- 2013-11-12 EA EA201590877A patent/EA201590877A1/ru unknown
- 2013-11-12 AU AU2013345018A patent/AU2013345018A1/en not_active Abandoned
- 2013-11-12 EP EP13795943.3A patent/EP2920211A1/en not_active Withdrawn
- 2013-11-12 WO PCT/US2013/069673 patent/WO2014078306A1/en active Application Filing
- 2013-11-12 JP JP2015542013A patent/JP2016502520A/ja active Pending
- 2013-11-12 CN CN201380059370.6A patent/CN104781280A/zh active Pending
- 2013-11-12 KR KR1020157012416A patent/KR20150084007A/ko not_active Application Discontinuation
- 2013-11-12 US US14/078,024 patent/US20140134189A1/en not_active Abandoned
- 2013-11-12 CA CA2891327A patent/CA2891327A1/en not_active Abandoned
- 2013-11-12 BR BR112015010691A patent/BR112015010691A2/pt not_active Application Discontinuation
-
2015
- 2015-04-03 US US14/678,347 patent/US9951132B2/en active Active
- 2015-04-14 ZA ZA2015/02516A patent/ZA201502516B/en unknown
- 2015-04-23 PH PH12015500903A patent/PH12015500903A1/en unknown
- 2015-05-04 IL IL238629A patent/IL238629A0/en unknown
- 2015-05-08 CL CL2015001237A patent/CL2015001237A1/es unknown
- 2015-05-12 CO CO15108080A patent/CO7400866A2/es unknown
- 2015-10-28 HK HK15110658.5A patent/HK1210182A1/xx unknown
-
2018
- 2018-03-20 US US15/926,223 patent/US20180208656A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2016502520A (ja) | 2016-01-28 |
| EP2920211A1 (en) | 2015-09-23 |
| HK1210182A1 (en) | 2016-04-15 |
| SG11201502933UA (en) | 2015-05-28 |
| CA2891327A1 (en) | 2014-05-22 |
| AU2013345018A1 (en) | 2015-05-14 |
| US20180208656A1 (en) | 2018-07-26 |
| CN104781280A (zh) | 2015-07-15 |
| MX2015005546A (es) | 2015-08-05 |
| IL238629A0 (en) | 2015-06-30 |
| CO7400866A2 (es) | 2015-09-30 |
| US20140134189A1 (en) | 2014-05-15 |
| US20150266957A1 (en) | 2015-09-24 |
| ZA201502516B (en) | 2016-01-27 |
| KR20150084007A (ko) | 2015-07-21 |
| WO2014078306A1 (en) | 2014-05-22 |
| BR112015010691A2 (pt) | 2017-08-22 |
| PH12015500903A1 (en) | 2015-07-13 |
| US9951132B2 (en) | 2018-04-24 |
| EA201590877A1 (ru) | 2015-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO7020859A2 (es) | Anticuerpos anti-cd134 (ox40) y usos de los mismos | |
| BR112015004397A2 (pt) | formulações de anticorpos de receptor anti-prolactina. | |
| CL2016000251A1 (es) | Anticuerpos anti-activina y usos de los mismos | |
| CO6821892A2 (es) | Anticuerpos anti-angptl3 y usos de los mismos | |
| CO6940383A2 (es) | Anticuerpos anti-erbb3 y usos de los mismos | |
| CL2015001924A1 (es) | Anticuerpos anti-pdgfr-beta y usos relacionados. | |
| CO7061078A2 (es) | Compuestos de enediino, conjugados de los mismos y sus usos y metodos | |
| BR112015001459A2 (pt) | anticorpos anti-kit e usos dos mesmos. | |
| DK2997134T3 (da) | Human anvendelse af genmanipulerede kimære antigenreceptor-(car)-t-celler | |
| BR112015014063A2 (pt) | anticorpos anti-b7-h4 humano e seus usos. | |
| DK3375333T3 (da) | System til tilberedning af drikkevarer | |
| BR112015002790A2 (pt) | anticorpos asgpr e usos dos mesmos. | |
| BR112014001030A2 (pt) | anticorpos anti-receptor alfa de folato e usos destes | |
| DK2934584T3 (da) | Anti-gdf15-antistoffer | |
| CL2015001266A1 (es) | Anticuerpos de antihemaglutinina y métodos de uso. | |
| DK2850101T3 (da) | Anti-FcRn-antistoffer | |
| DK3117837T3 (da) | Antistofformuleringer | |
| FR2986625B1 (fr) | Dispositif electrocommandable | |
| CO6940376A2 (es) | Anticuerpos anti-psgl-1 y usos de los mismos | |
| CL2014002019A1 (es) | Anticuerpos anti - asic1; composicion farmaceutica que lo comprende y usos de los mismos. | |
| CL2014003372A1 (es) | Proteinas fijadoras de antigeno antagonistas del receptor de accion dual y sus usos | |
| BR112014009178A2 (pt) | métodos, uso, receptor e invenção | |
| DK2828292T3 (da) | Jcv-neutraliserende antistoffer | |
| CO6862154A2 (es) | Metabolitos de trans-clomifeno y usos de los mismos | |
| DK3521315T3 (da) | Anti-transglutaminase-2-antistoffer |